Germany: Patent Term Extension For Medical Devices: New Opportunities, Open Questions

Last Updated: 11 February 2011
Article by Christian Fulda, Niklas Piening and Martin Weber

The first German patent term extension granted for a medical device, a combination product, may open the door for extended patent protection for combination products. It thus offers new opportunities in product development. At the same time, a number of questions remain open, in particular in the light of conflicting case law.

New Opportunities

On August 19, 2010, the German Patent Office published the grant of a Supplementary Protection Certificate ("SPC") for a medical device, glass microspheres with the radiopharmaceutical Yttrium-90. The issuance came as no surprise, as it followed in the wake of a decision of the 14th Senate of the German Federal Patent Court ("Bundespatentgericht" or "BPatG") dated January 26, 2010 (Case 14 W (pat) 12/07). This decision had overturned an earlier rejection of the Patent Office and granted an SPC for "Yttrium-90 glass microspheres."

The door may thus be open for applications for patent term extensions in Germany for medical devices, at least for combination products, and the same is true in The Netherlands. Based on the precedents, similar decisions in other jurisdictions of the European Economic Area are conceivable. Accordingly, manufacturers may seek to improve on the life cycle management of a patented product by extending the patent protection, and thus improve on the rate of return on investment. In addition, new product development opportunities present themselves. At the same time, a decision of the 15th Senate of the Bundespatentgericht calls into question the eligibility of medical devices, alone or in combination with pharmaceuticals. Careful attention also needs to be paid to the regulatory category of a product and to the claims of the patent in question.

Accordingly, with regard to the development of new products, the clinical mode of action has to be carefully scrutinized. And during prosecution, even if the focus is on the use by a "material only" medical device, not by a combination product, the latter use should be anticipated as optional and thus provided for in the claims.

The German Case

The German Federal Patent Court had to decide on an application for an SPC for the product "Yttrium-90 glass microspheres," authorized as "Therasphere® Yttrium-90 Glass Microspheres." The applicant was the patent proprietor of EP 0 201 601, including its German part (DE 35 86 129), the basic patent in the terminology of the European legislation on SPCs (Regulation 469/2009/EC, the "SPC Regulation"). The basic patent was still in force at the time the SPC application was filed. The Office had rejected the application on the grounds that under the SPC Regulation, only products that had obtained a marketing authorization according to the Community Code for Medicinal Products for Human Use (directive 2001/83/EC, the "Community Code"), i.e., as a pharmaceutical, were eligible for an SPC.

The court disagreed. It pointed out that under the European legislation on medical devices, combination products, i.e. products that also contain an active pharmaceutical ingredient ("API"), require an assessment of the API according to the Community Code in the context of the conformity assessment of the medical device. For this purpose, the Notified Body selected by the manufacturer to assess and certify the device has to submit the dossier for the API to the European Medicines Agency or a national authority within the EU competent to approve pharmaceuticals. Only upon review and confirmation of the API dossier is the Notified Body entitled to issue a certification for the medical device.

Accordingly, the court held that while no marketing authorization for a pharmaceutical is issued, such a combination product still undergoes the review and approval under the Community Code. Therefore, by analogy, the SPC Regulation applied to such medical device in case of certification.

The court found that the other preconditions for an SPC were fulfilled. The product was covered by a valid patent in force at the time of the application for patent term extension. The application sought the first SPC for the product. And the certification of the medical devices was the first marketing authorization (in the terms of the SPC Regulation) for the product (i.e., the combination of Yttrium-90 and glass microspheres). The patent term extension was calculated according to the rules of the SPC Regulation, leading to an SPC valid for five years after expiry of the original term of the basic patent.

Open Questions

The court, in discussing whether the device constituted a "product" in the sense of the SPC Regulation, held that the glass microspheres containing the radiopharmaceutical Yttrium-90 not only incorporated the API, but also constituted a medicinal product. The court referred to the definition of a "radiopharmaceutical" in the Community Code, which requires an API in a formulation ready for use. At the same time, the court held that the definition of "active implantable medical device" according to directive 90/385/EEC was met as well. The product had a therapeutic purpose, was applied parenterally, and remained at its site of application within the body.

However, from a European regulatory perspective, a product can only be either a medicinal product or a medical device. The distinction is made according to the predominant mode of action. If it is predominantly pharmacological, immunological, or metabological, it is a medicinal product; otherwise, it is a medical device. The court did not discuss the mode of action but accepted the product as a certified medical device. The question remains whether the case law applies only to combination products with a composition comparable to a pharmaceutical formulation, as the microspheres in this case, or also to other compositions, e.g., drug-eluting stents or other implants combined with API. Given the fact that the latter products have to undergo, within the conformity assessment, a review and approval of the API dossier according the Community Code, the case law should be applied to such products as well.

From a patent prosecution perspective, it is of note that the basic patent explicitly referenced Yttrium-90 as API to be incorporated in the claimed microspheres. This leads to the question whether only combination products that incorporate an API explicitly mentioned in a claim of the basic patent are eligible for patent term extensions. Drawing on the case law on SPCs for fixed-combination medicinal products, it should be sufficient if there is an "identifier" in the basic patent to the medical device's use in a composition with an API. Thus, patent applications referring to medical devices should seek to contain claims under which the invention in question may be used alone or in combination with an API.

With regard to the preconditions under the SPC Regulation, it is of interest that the court referred to the "marketing authorization" (i.e., conformity assessment) for the combination product, not for the API (which had undergone the review and approval under the Community Code, and thus made the product eligible for an SPC). The API itself, Yttrium-90, is a well-known API that had been approved as a radiopharmaceutical earlier. In this context, it is important to note that in other cases, the Court of Justice of the European Union (the "CJEU") held that a known and approved API that comes in the form of a new controlled release formulation would not be eligible for patent term extension (such as Gliadel®, a medicinal product to be implanted into the cranium for the treatment of recurrent brain tumors, where carmustine, a highly cytotoxic active ingredient, is released slowly and gradually by the polifeprosan, which acts as a bioerodible matrix; Case C-431/04).

Given that the patent term extension under the SPC Regulation is granted in view of the lengthy pre-clinical and clinical development for pharmaceuticals, the question is whether the case law also applies to combination products, which draw on bibliographical data for the API dossier, or whether the review under the Community Code has to be carried out with specific data obtained in clinical trials with the combination product. However, a revision to the European medical devices legislation that entered into force in 2009 tightened the requirements for clinical trials of medical devices. Therefore, combination product medical devices in all likelihood will have to undergo clinical trials. The question will thus probably remain academic in most cases; such specific clinical data will have to be generated for the medical device conformity assessment.

Of a more fundamental nature is the question whether medical devices without an additional API are eligible for patent term extension in the EU. Conventional wisdom holds this not to be the case. Considering that the patent term extension is intended to compensate for long development timelines required for regulatory product approvals, it would be a logical conclusion to extend the analogy under the SPC to medical devices as such, at least to those that under the revised medical devices legislation have to undergo comprehensive clinical trials, thus significantly lengthening the development timeline. Whether courts would accept such analogy, or rather deem this a policy decision, remains an open question.

The 15th Senate of the Bundespatentgericht has answered this question in the negative (case 15 W (pat) 28/08) but has allowed an appeal to the German Federal Court of Justice in Civil Matters ("Bundesgerichtshof" or "BGH"). In that case, the basic patent covered a method for preparing hylan and novel hylan product. The applicant had applied for an SPC for the combination of "Hylan A and Hylan B" and had referred to the certificate of a notified body on the conformity assessment according to the medical devices directive 93/42/EC. That case, therefore, did not involve a medical device plus pharmaceutical active ingredient product, but a product that had been authorized only via the regulatory pathway for medical devices. The 15th Senate confirmed the rejection of the application by the German Patent Office on the grounds that medical devices cannot be the object of an SPC. It denied that the preconditions for an analogy were met, given that the SPC Regulation had been revised multiple times, and only recently had been codified again after subsequent amendments in 2009. In all those years, medical devices had already been known, but the legislator had not taken the decision to include them in the scope of the SPC Regulation.

This is not the most compelling argument, as the 15th Senate failed to demonstrate that the issue of extending the SPC Regulation to medical devices had ever been brought to the attention of the legislator. In that regard, it has to be kept in mind that the threshold for obtaining a marketing authorization has been lower for medical devices, compared to medicinal products. Thus, development timelines have been faster, and there has not been much need for patent term extension. This has now changed, since medical devices, depending on their classification, also have to undergo strict clinical trials, with all the ensuing impact on development timelines.

The second argument of the 15th Senate is that the SPC Regulation requires an "authorization" in accordance with the Community Code, and that even in the case of combination products, the review carried out by an authority for the pharmaceutical part of the medical device does not formally qualify as an authorization. This is not compelling, either, as the reference to the authorization under the Community Code in substance reflects the comprehensive pre-clinical and clinical development efforts required for such authorization. And the same efforts have to be carried out for the pharmaceutical part of a medical device.


Patent term extensions for combination product medical devices currently are based on a limited number of cases in Europe, and the case law of the Bundespatentgericht is conflicting. Further cases may shed light on the open questions discussed above, in particular any decision of the Bundesgerichtshof on appeal against the rejection by the 15th Senate of the Bundespatentgericht. It is of note that on a European level, only the CJEU will be in the position to render decisions that are binding for all Member States. However, applicants cannot appeal to the CJEU but have to rely on their national courts to submit a request for a preliminary judgment to the CJEU.

With regard to the question of patent term extensions for medical devices as such, industry should seek to convince the European legislators to extend the SPC Regulation to medical devices, in view of lengthening development timelines, or to create similar provisions specifically for medical devices.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Christian Fulda
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions